Statin Prevents Events in Patients With IFG

Major Finding: In patients with impaired fasting glucose, rosuvastatin was associated with a 32% reduction in the risk of major adverse coronary events, but also with increased new-onset diabetes.

Source of Data: 5,504 participants with impaired fasting glucose at baseline in the JUPITER trial.

Disclosures: JUPITER was funded by AstraZeneca. Dr. Pradhan disclosed having no relevant financial conflicts.